Journal article
Comparison of Three Jet Nebulizer Aerosol Delivery Systems Used to Administer Recombinant Human DNase I to Patients With Cystic Fibrosis
Chest, v 108(1), pp 153-156
Jul 1995
PMID: 7606951
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Study objective: To compare the degree of improvement in pulmonary function achieved with recombinant human DNase I (rhDNase) administered by three different aerosol delivery systems: DeVilbiss Pulmo-Aide compressor with the Marquest Acorn II nebulizer, the Hudson T Up-draft nebulizer, and the Pari LC Jet Plus nebulizer with the Pari Inhalier Boy compressor. These produce similar aerosols in vitro in terms of size distribution and activity of delivered rhDNase.
Study design: Multicenter, randomized, open-label, parallel-group comparison of changes from baseline in pulmonary function variables in each test group. Patients were treated with rhDNase (2.5 mg bid) for 15 days, administered with three different aerosol delivery systems.
Setting: Outpatient clinics at 26 sites in the United States.
Patients: 397 patients >5 years of age with cystic fibrosis and baseline forced vital capacity (FVC) values between 40 and 70% of predicted values.
Results: All three nebulizers gave comparable improvements in pulmonary function. FEV1 increased by an average of 13.2 to 14.1%, FVC by 10.9 to 11.8%, and forced midexpiratory flow (FEF25-75) by 16.5 to 17.1%. No unusual or unexpected adverse events were reported other than those that would be expected in patients with cystic fibrosis.
Conclusions: Recombinant human DNase I produced a similar magnitude of improvement in the pulmonary function of patients with cystic fibrosis when the drug was administered using three different types of nebulizer systems with similar in vitro delivery and safety characteristics.
Metrics
14 Record Views
Details
- Title
- Comparison of Three Jet Nebulizer Aerosol Delivery Systems Used to Administer Recombinant Human DNase I to Patients With Cystic Fibrosis
- Creators
- Stanley B. Fiel - From Pulmonary and Critical Care Medicine, and the Adult Cystic Fibrosis Program, Medical College of Pennsylvania, Philadelphia, (Dr. Fiel), and Genentech Inc, South San Francisco (Drs. Fuchs, Johnson, Gonda, and Clark)Henry J. Fuchs - From Pulmonary and Critical Care Medicine, and the Adult Cystic Fibrosis Program, Medical College of Pennsylvania, Philadelphia, (Dr. Fiel), and Genentech Inc, South San Francisco (Drs. Fuchs, Johnson, Gonda, and Clark)Charles Johnson - FuchsIgor Gonda - From Pulmonary and Critical Care Medicine, and the Adult Cystic Fibrosis Program, Medical College of Pennsylvania, Philadelphia, (Dr. Fiel), and Genentech Inc, South San Francisco (Drs. Fuchs, Johnson, Gonda, and Clark)Andrew B. Clark - From Pulmonary and Critical Care Medicine, and the Adult Cystic Fibrosis Program, Medical College of Pennsylvania, Philadelphia, (Dr. Fiel), and Genentech Inc, South San Francisco (Drs. Fuchs, Johnson, Gonda, and Clark)Crystal Johnson - Accelerated Career Entry Bachelor of Science in Nursing (BSN)
- Publication Details
- Chest, v 108(1), pp 153-156
- Publisher
- Elsevier
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Accelerated Career Entry Bachelor of Science in Nursing (BSN); Music
- Web of Science ID
- WOS:A1995RJ22200031
- Scopus ID
- 2-s2.0-0029046164
- Other Identifier
- 991019183970304721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- Web of Science research areas
- Critical Care Medicine
- Respiratory System